Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1920MR)

This product GTTS-WQ1920MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species synthetic construct
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ1920MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6184MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CP-870893
GTTS-WQ8263MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HLX10
GTTS-WQ1858MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AG1-25
GTTS-WQ10557MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY­3074828
GTTS-WQ9516MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA J-591
GTTS-WQ1425MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACA125
GTTS-WQ9454MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IPH4102
GTTS-WQ10727MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA M-281
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW